AKT1 and gastric cancer: These data are in accordance with recent studies showing that the attenuation of PI3K/AKT signaling pathways by Ropivacaine play an inhibitory effect on the proliferation, migration and invasion of GC, thus suggesting a new therapeutic target for GC drugs (70, 71).